Metabolic
Retatrutide
Retatrutide (triple GIP/GLP-1/glucagon receptor agonist)
Retatrutide is a single-molecule triple agonist acting at the GIP, GLP-1, and glucagon receptors. The inclusion of glucagon receptor agonism is mechanistically distinct from dual agonists: glucagon receptor activation is studied for effects on hepatic lipid handling and energy expenditure, pathways not engaged by incretin agonism alone. It remains investigational and is a frequent subject of comparative receptor-pharmacology work.
Research applications
- Triple receptor agonism and pathway-contribution studies
- Hepatic lipid metabolism research in preclinical models
- Energy expenditure and thermogenesis pathway assays
- Head-to-head comparison against dual agonists
Storage
Store lyophilized powder at -20°C protected from light. Reconstituted solution stable at 2-8°C for up to 30 days.
Reconstitution
Reconstitute with bacteriostatic water directed down the vial wall. Swirl gently until dissolved.
Published literature
161 papers indexed on PubMed for Retatrutide. Showing 6, reviews first.
- 01Retatrutide-A Game Changer in Obesity Pharmacotherapy
Katsi V et al. · Biomolecules · 2025
- 02What is the pipeline for future medications for obesity?
Melson E et al. · Int J Obes (Lond) · 2025
- 03Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity
Drucker DJ · Diabetes Care · 2024
- 04Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition?
Locatelli JC et al. · Diabetes Care · 2024
- 05Gut hormones and appetite regulation
Hong SH, Choi KM · Curr Opin Endocrinol Diabetes Obes · 2024
- 06
Indexed from PubMed, 2026-07-19. We link to sources rather than reproducing them.
Related compounds
Semaglutide
5–20mg · COA published
Long-acting GLP-1 receptor agonist studied extensively for incretin pathway signaling and glucose regulation in preclinical models.
- CAS
- 910463-68-2
- MW
- 4113.58
- Purity
- Per published certificate
Tirzepatide
10–30mg · COA published
Dual GIP and GLP-1 receptor agonist — a 39-amino-acid synthetic peptide studied for combined incretin pathway activity.
- CAS
- 2023788-19-2
- MW
- 4813.45
- Purity
- Per published certificate
Cagrilintide
10mg · COA published
Long-acting amylin analog studied at calcitonin and amylin receptors — a satiety pathway mechanistically distinct from incretin agonism.
- CAS
- 1415456-99-3
- MW
- 4409
- Purity
- Per published certificate
AOD-9604
5mg · COA published
C-terminal fragment of human growth hormone studied for lipolytic activity without the growth-promoting effects of the full hormone.
- CAS
- 221231-10-3
- MW
- 1815.08
- Purity
- Per published certificate
How Retatrutide compares
Side-by-side against the compounds researchers most often weigh it against, with price per milligram, mechanism and the published certificate for each.
Semaglutide vs Retatrutide
The two ends of the incretin design space: a selective GLP-1 analog against a triple agonist.
Tirzepatide vs Retatrutide
Dual versus triple agonism. The question is what glucagon receptor activation adds beyond incretin signaling.
AOD-9604 vs Retatrutide
Cagrilintide vs Retatrutide
Retatrutide
From $99